Dr Reddys Laboratories (RDY) Total Long Term Debt (2009 - 2023)

Dr Reddys Laboratories (RDY) has reported Total Long Term Debt for 14 consecutive years, with $153.0 million the latest figure, recorded in Q2 2023.

• Quarterly Total Long Term Debt fell 49.17% year-over-year to $153.0 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $153.0 million (down 49.17% YoY) and the FY2023 annual result came in at $164.0 million, changed N/A from the prior year.
• Total Long Term Debt declined to $153.0 million in Q2 2023 per RDY's latest filing, from $164.0 million in the prior quarter.
• Over the last five years, Total Long Term Debt for RDY reached as high as $442.0 million in Q3 2019 and fell as low as $153.0 million in Q2 2023.
• A 4-year average of $277.1 million and a median of $280.0 million in 2020 frame the typical range for Total Long Term Debt.
• Annual changes were most pronounced in 2019 — Total Long Term Debt tumbled 63.52% — and 2020, when it gained 25.0%.
• Year by year, Total Long Term Debt stood at $224.0 million in 2019, then rose by 25.0% to $280.0 million in 2020, then gained by 7.5% to $301.0 million in 2022, then tumbled by 49.17% to $153.0 million in 2023.
• According to Business Quant data, Total Long Term Debt over the past three periods registered $153.0 million, $164.0 million, and $301.0 million for Q2 2023, Q1 2023, and Q2 2022 respectively.